MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/bco2.70212

Медицинская библиотека · BJUI compass · 2026

Bone scan index rise prior to osteonecrosis of the jaw with bone-modifying agents in prostate cancer.

Tani Masaru, Hatano Koji, Kamiya Takashi, Konishi Masatoshi, Matsukawa Atsuki, Horitani Hiromu, Inoguchi Syunsuke, Kanaki Tomohiro, Yoshimura Akihiro, Horibe Yuki, Liu Yutong, Sassi Nesrine, Oka Toshiki, Okuda Yohei, Yamamichi Gaku, Ishizuya Yu, Hayashi Takuji, Yamamoto Yoshiyuki, Kato Taigo, Watabe Tadashi, Kawashima Atsunari, Isohashi Kayako, Nonomura Norio

СтатьяПеревод в очереди

Аннотация

OBJECTIVE

This study aimed to evaluate the maximum bone scan index in the jaw (BSIJmax) before the development of clinical medication-related osteonecrosis of the jaw (MRONJ) in patients with prostate cancer.

METHODS

We retrospectively analysed 135 patients with prostate cancer and bone metastases who received bone-modifying agents (BMAs) between 2008 and 2025. Bone scintigraphy data were collected at baseline and during the BMA treatment. BSIJmax was calculated using computer-assisted diagnostic software (BONENAVI). Primary endpoints were BSIJmax in the maxilla and mandible before the clinical diagnosis of MRONJ, compared with baseline values. Secondary endpoints included area under the receiver operating characteristic curves (AUCs) for diagnosing MRONJ using BSIJmax in the maxilla and mandible.

RESULTS

Among 135 patients, 27 developed MRONJ during a median follow-up of 74 months (interquartile range, 41-124 months). Mandibular BSIJmax values before the clinical diagnosis of MRONJ were significantly higher than baseline values (0.090 vs. 0.027, p < 0.001), whereas maxillary values showed no significant change. The AUC for mandibular BSIJmax in diagnosing MRONJ was 0.803. A mandibular BSIJmax cut-off of 0.033 yielded a sensitivity and specificity of 85% and 71%, respectively, for the diagnosis of MRONJ.

CONCLUSION

The mandibular BSIJmax increased before the clinical diagnosis of MRONJ. The incorporation of BSIJmax into bone scintigraphy may enable early detection of MRONJ and timely intervention in patients with prostate cancer receiving BMA therapy.

Для цитирования: Tani Masaru, Hatano Koji, Kamiya Takashi, Konishi Masatoshi, Matsukawa Atsuki, Horitani Hiromu, Inoguchi Syunsuke, Kanaki Tomohiro, Yoshimura Akihiro, Horibe Yuki, Liu Yutong, Sassi Nesrine, Oka Toshiki, Okuda Yohei, Yamamichi Gaku, Ishizuya Yu, Hayashi Takuji, Yamamoto Yoshiyuki, Kato Taigo, Watabe Tadashi, Kawashima Atsunari, Isohashi Kayako, Nonomura Norio. Bone scan index rise prior to osteonecrosis of the jaw with bone-modifying agents in prostate cancer.. BJUI compass. 2026. DOI: 10.1002/bco2.70212.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.